CFO
IMCR icon

CVA Family Office’s Immunocore IMCR Stock Holding History

CVA Family Office’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32
Closed -$965 – 1848
2026
Q1 		$965 Buy
+32
New +$1.03K ﹤0.01% 1659
2025
Q4 		– Sell
-34
Closed -$1.24K – 1326
2025
Q3 		$1.24K Buy
+34
New +$1.16K ﹤0.01% 1093
2024
Q3 		– Sell
-22
Closed -$746 – 1309
2024
Q2 		$746 Buy
22
+8
+57% +$408 ﹤0.01% 1109
2024
Q1 		$910 Buy
+14
New +$961 ﹤0.01% 1008

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

CVA Family Office's IMCR Position: Q2 2026 in Review

CVA Family Office sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 32 shares — an estimated $965 sold.

CVA Family Office first reported a position in IMCR in Q1 2024 and held it in 4 quarters. The position peaked at $1.24K in Q3 2025. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • CVA Family Office reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • CVA Family Office sold 32 Immunocore shares in Q2 2026, an estimated $965.
  • CVA Family Office first reported a position in Immunocore in Q1 2024 and held it in 4 quarters.
  • CVA Family Office's Immunocore position peaked at $1.24K in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.